Safinamide Mesylate

甲磺酸沙非胺

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameSafinamide Mesylate
Drug Alias NameSafinamide mesilate甲磺酸沙非胺沙芬酰胺甲磺酸盐safinamidumsafinamide +[19] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate release inhibitorsMonoamine oxidase B inhibitorsPolyamine uptake inhibitors
TargetsMonoamine oxidase B
Therapy Area/IndicationsRenal InsufficiencyDyskinesia, Drug-InducedParkinson Disease +[5] 
Global Approved IndicationsParkinson Disease
Approved Indications in ChinaParkinson Disease
Original Approved Country/TerritoryEU
Original Approved Date2015/02/23
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNewron Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesZambonZambon SpaMeiji Seika Pharmatech Co Ltd +[4] 
Inactive CompaniesNewron Pharmaceuticals Spa
Active IndicationsParkinson Disease
Inactive IndicationsRenal InsufficiencyDyskinesia, Drug-InducedMultiple System Atrophy +[4] 

Other Information

ATC CodeN04B
Related LinksWikipediaDrugBankKEGG